Phaseline

Targets › RHCE

RHCE (Blood group Rh(CE) polypeptide): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Hematology; next expected readout Apr 2029.

Component of the ankyrin-1 complex, a multiprotein complex involved in the stability and shape of the erythrocyte membrane. Mediates the primary membrane attachment site for ANK1 when associated with RHAG. May participate in the ammonium and carbon dioxide transport through the heterotrimer form (Probable). (UniProt, P18577)

Open in Phaseline: the race on RHCE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Children's Hospital of PhiladelphiaRH genotype matched RBC transfusions
Transfusion of red blood cells matched at RHD and RHCE loci to reduce alloimmunization
RHD, RHCEPhase 1Sickle Cells DiseaseApr 2029

Conditions

Sickle Cells Disease (1)

Modalities

other (1)

Companies

Children's Hospital of Philadelphia (1)

Related targets

RHD (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.